Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer.

ABSTRACT:

Background

Poly (ADP-ribose) polymerase (PARP) inhibitors have been increasingly used in the treatment of ovarian cancer, with BRCA positivity and homologous recombination deficiency (HRD) being common biomarkers used for predicting their efficacy. However, given the limitations of these biomarkers, new ones need to be explored.

Methods

This retrospective study included 181 ovarian cancer patients who received olaparib or niraparib at two independent hospitals in Japan between May 2018 and December 2022. Clinical information and blood sampling data were collected. Patient characteristics, treatment history, and predictability of treatment duration based on blood data before treatment initiation were examined.

Results

High-grade serous carcinoma, BRCA positivity, HRD,

SUBMITTER: Uekusa R 

PROVIDER: S-EPMC10993710 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature